Peptide Therapeutics To Retain Vaccines; Spins Off Small Molecules
Executive Summary
Cambridge, U.K.-based Peptide Therapeutics will retain its travel vaccine focus, following the spin off of its drug discovery activities into a new entity called NewCo.
You may also be interested in...
Baxter Adds Vaccine Production Capacity Via Peptide Therapeutics Deal
Baxter is enhancing its vaccine production capacity via a $40 mil. equity investment in Peptide Therapeutics.
Baxter Adds Vaccine Production Capacity Via Peptide Therapeutics Deal
Baxter is enhancing its vaccine production capacity via a $40 mil. equity investment in Peptide Therapeutics.
Medeva
Discussions of a cash offer for the firm "have now been terminated," Medeva announced Sept. 17. "The proposal received turned out to be at an opportunistic price which the board [of Medeva], advised by Lazard Brothers, had no hesitation in rejecting." Elan had been rumored to be the suitor (1"The Pink Sheet" Sept. 13, p. 4). At a Bear Stearns conference Sept. 15, Elan Exec VP-Business Development Michael Sember said that after several sizeable acquisitions in 1998, the company has been in a "breathing period...focusing on integrating these business units"